iBio, Inc. Common Stock Total Liabilities
iBio, Inc. Common Stock total liabilities. Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has total liabilities worth $13.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check iBio, Inc. Common Stock (IBIO) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of iBio, Inc. Common Stock (2007–2026)
Total liabilities of iBio, Inc. Common Stock from 2007 to 2026. This chart illustrates how iBio, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore iBio, Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
iBio, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of iBio, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yoong Onn Corporation Bhd
KLSE:5159
|
Malaysia | RM62.82 Million |
|
Xin Chio Global Co Ltd
TWO:3171
|
Taiwan | NT$668.54 Million |
|
CONCORD ENVIRO SYSTEMS L
NSE:CEWATER
|
India | Rs-5.72 Billion |
|
Top Win International Limited
NASDAQ:SORA
|
USA | $2.30 Million |
|
Senzime AB
ST:SEZI
|
Sweden | Skr61.56 Million |
|
Rock Tech Lithium Inc
V:RCK
|
Canada | CA$2.19 Million |
|
Iconic Worldwide Bhd
KLSE:9113
|
Malaysia | RM127.77 Million |
|
THN Corporation
KO:019180
|
Korea | ₩418.07 Billion |
Liability Composition Analysis (2007–2026)
This chart breaks down iBio, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is iBio, Inc. Common Stock's balance sheet.
Liquidity & Leverage Metrics
iBio, Inc. Common Stock Total Liabilities Ratios Explained
iBio, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how iBio, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for iBio, Inc. Common Stock (2007–2026)
The table below shows the annual total liabilities of iBio, Inc. Common Stock from 2007 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $13.40 Million | +61.31% |
| 2025-06-30 | $8.30 Million | +12.08% |
| 2024-06-30 | $7.41 Million | -71.31% |
| 2023-06-30 | $25.83 Million | -28.10% |
| 2022-06-30 | $35.92 Million | -6.46% |
| 2021-06-30 | $38.40 Million | +2.18% |
| 2020-06-30 | $37.58 Million | +33.61% |
| 2019-06-30 | $28.13 Million | +4.49% |
| 2018-06-30 | $26.92 Million | -0.65% |
| 2017-06-30 | $27.09 Million | -1.67% |
| 2016-06-30 | $27.56 Million | +2081.79% |
| 2015-06-30 | $1.26 Million | +219.75% |
| 2014-06-30 | $395.00K | -90.78% |
| 2013-06-30 | $4.29 Million | +19.20% |
| 2012-06-30 | $3.60 Million | -49.64% |
| 2011-06-30 | $7.14 Million | +85.24% |
| 2010-06-30 | $3.85 Million | +610.91% |
| 2009-06-30 | $542.14K | -94.44% |
| 2008-06-30 | $9.75 Million | +20.37% |
| 2007-06-30 | $8.10 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimiz… Read more